Literature DB >> 9635546

The use of lithium to augment antidepressant medication.

F Rouillon1, P Gorwood.   

Abstract

Lithium is one of the most studied agents used to augment the pharmacologic effect of antidepressant drugs, particularly in refractory depression. We reviewed 22 case reports, 22 open trials, 5 open comparison studies, and 9 placebo-controlled studies of lithium augmentation and 6 studies in which antidepressants were added to, or coadministrated with, lithium. The efficacy of the augmentation therapeutic strategy is supported by these analyses, involving 969 patients. The optimal dose and the most effective blood levels of lithium are unclear, but a reasonable strategy would be to start with low doses (600-900 mg/day) and, if necessary, to increase the doses to obtain a level in accordance with the usual therapeutic range of blood levels (0.8-1.2 mEq/L). Some patients respond quickly, but others need a long and combined treatment; it is thus advantageous to prescribe lithium for at least 3 to 6 weeks. Despite the fact that the mechanism of action of lithium augmentation is still unknown, all refractory depressed patients can potentially be treated by lithium augmentation, particularly bipolar patients, to obtain full prophylactic effect as soon as possible.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9635546

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  8 in total

Review 1.  Fortnightly review: drug treatment of depression.

Authors:  O Spigset; B Mårtensson
Journal:  BMJ       Date:  1999-05-01

2.  Comparison of lithium concentrations in red blood cells and plasma in samples collected for TDM, acute toxicity, or acute-on-chronic toxicity.

Authors:  M Camus; G Henneré; G Baron; G Peytavin; L Massias; F Mentré; R Farinotti
Journal:  Eur J Clin Pharmacol       Date:  2003-09-19       Impact factor: 2.953

3.  An Evidence-Based Approach to Augmentation and Combination Strategies for: Treatment-Resistant Depression.

Authors:  Jeremy Barowsky; Thomas L Schwartz
Journal:  Psychiatry (Edgmont)       Date:  2006-07

4.  Medicine Cabinet: Drug treatment of depression.

Authors:  B Martensson; O Spigset
Journal:  West J Med       Date:  1999-08

5.  Pharmacologic Activation of Wnt Signaling by Lithium Normalizes Retinal Vasculature in a Murine Model of Familial Exudative Vitreoretinopathy.

Authors:  Zhongxiao Wang; Chi-Hsiu Liu; Ye Sun; Yan Gong; Tara L Favazza; Peyton C Morss; Nicholas J Saba; Thomas W Fredrick; Xi He; James D Akula; Jing Chen
Journal:  Am J Pathol       Date:  2016-08-12       Impact factor: 4.307

Review 6.  Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Guangjian Li; Xu Wang; Dihui Ma
Journal:  Clin Drug Investig       Date:  2016-07       Impact factor: 2.859

Review 7.  Treatments in depression.

Authors:  Fabrice Duval; Barry D Lebowitz; Jean-Paul Macher
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

8.  Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults.

Authors:  Xinyan Zhang; Yuchun Cai; Xiaowen Hu; Christine Y Lu; Xiaoyan Nie; Luwen Shi
Journal:  Front Psychiatry       Date:  2022-06-24       Impact factor: 5.435

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.